Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityActive in the last 2 years

Guolin Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7047-6499; OpenAlex author ID A5101764545. Sources: OpenAlex.

Their work

Papers
16 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
55
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: 3 papers · 2019: 2 papers · 2020: 1 paper · 2021: 2 papers · 2022: 2 papers · 2023: none · 2024: 1 paper · 2025: 2 papers · 2026: 1 paper

Papers 16

  1. USP10 promotes cell proliferation and gemcitabine resistance in pancreatic cancer by the regulation of IGF2BP3-STEAP3. Last author DOI 10.1038/s41388-025-03654-z↗
  2. Cancer-associated fibroblast-derived circKLHL24 drives perineural invasion in pancreatic cancer via dual regulation of the sec31a-CXCL12 axis. Co-author DOI 10.1186/s13046-025-03489-2↗
  3. The triglyceride-glucose index associated with reduced risk of liver metastasis in pancreatic cancer. Last author DOI 10.3389/fendo.2025.1592788↗
  4. Extracellular vesicle-packaged PIAT from cancer-associated fibroblasts drives neural remodeling by mediating m5C modification in pancreatic cancer mouse models. Co-author DOI 10.1126/scitranslmed.adi0178↗
  5. Corrigendum to "Macrophage-expressed CD51 promotes cancer stem cell properties via the TGF-β1/smad2/3 axis in pancreatic cancer" [Canc. Lett. 459(2019)204-215]. Co-author DOI 10.1016/j.canlet.2022.215897↗
  6. circFARP1 enables cancer-associated fibroblasts to promote gemcitabine resistance in pancreatic cancer via the LIF/STAT3 axis. Co-author DOI 10.1186/s12943-022-01501-3↗
  7. Correction: Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1/SATB-1 pathway in pancreatic cancer. Co-author DOI 10.1038/s41419-021-03420-5↗
  8. Cancer-associated fibroblasts-mediated ATF4 expression promotes malignancy and gemcitabine resistance in pancreatic cancer via the TGF-β1/SMAD2/3 pathway and A… Co-author DOI 10.1038/s41419-021-03574-2↗
  9. LLGL1 Regulates Gemcitabine Resistance by Modulating the ERK-SP1-OSMR Pathway in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.jcmgh.2020.06.009↗
  10. Macrophage-expressed CD51 promotes cancer stem cell properties via the TGF-β1/smad2/3 axis in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2019.06.005↗
  11. Excessive miR-25-3p maturation via N6-methyladenosine stimulated by cigarette smoke promotes pancreatic cancer progression. Co-author DOI 10.1038/s41467-019-09712-x↗
  12. FEZF1-AS1/miR-107/ZNF312B axis facilitates progression and Warburg effect in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41419-017-0052-1↗
  13. Tumor-associated macrophages promote progression and the Warburg effect via CCL18/NF-kB/VCAM-1 pathway in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41419-018-0486-0↗
  14. Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1/SATB-1 pathway in pancreatic cancer. Co-author DOI 10.1038/s41419-018-1104-x↗
  15. Endogenous miRNA Sponge LincRNA-ROR promotes proliferation, invasion and stem cell-like phenotype of pancreatic cancer cells. First author DOI 10.1038/cddiscovery.2017.4↗
  16. Long non-coding RNA LOC389641 promotes progression of pancreatic ductal adenocarcinoma and increases cell invasion by regulating E-cadherin in a TNFRSF10A-rela… Co-author DOI 10.1016/j.canlet.2015.12.010↗

Closest collaborators

The 25 strongest of 55 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shangyou Zheng · 12 shared papers, 2016–2025 · strength 1.30
  2. Quanbo Zhou · 9 shared papers, 2016–2022 · strength 0.81
  3. Lusheng Wei · 8 shared papers, 2017–2022 · strength 0.77
  4. Huilin Ye · 9 shared papers, 2016–2022 · strength 0.74
  5. Zhihua Li · 7 shared papers, 2018–2022 · strength 0.71
  6. Rufu Chen · 7 shared papers, 2016–2022 · strength 0.67
  7. Rihua He · 3 shared papers, 2022–2025 · strength 0.56
  8. Zhiqiang Fu · 7 shared papers, 2016–2021 · strength 0.54
  9. Tai-Jun Yi · 2 shared papers, 2025–2026 · strength 0.52
  10. Rufu Chen · 5 shared papers, 2018–2021 · strength 0.46
  11. Yimin Liu · 6 shared papers, 2016–2021 · strength 0.46
  12. Tianhao Huang · 2 shared papers, 2024–2025 · strength 0.41
  13. Chengyuan Hu · 2 shared papers, 2024–2025 · strength 0.41
  14. Rufu Chen · 2 shared papers, 2024–2025 · strength 0.41
  15. Changhao Chen · 3 shared papers, 2019–2024 · strength 0.41
  16. Chonghui Hu · 3 shared papers, 2019–2022 · strength 0.36
  17. Yong-Ling Liang · 1 shared paper, 2026 · strength 0.28
  18. Huimou Chen · 2 shared papers, 2016–2025 · strength 0.27
  19. Xingyu Li · 1 shared paper, 2025 · strength 0.24
  20. Shizong Li · 1 shared paper, 2025 · strength 0.22
  21. Tingting Li · 1 shared paper, 2025 · strength 0.22
  22. Bin Zhang · 2 shared papers, 2019–2022 · strength 0.22
  23. Xiang Zhang · 1 shared paper, 2024 · strength 0.19
  24. Yu Zhou · 1 shared paper, 2024 · strength 0.19
  25. Xiaohui Zhao · 3 shared papers, 2016–2018 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.